The store will not work correctly when cookies are disabled.
N-Hydroxy-2-[(4-nitro-benzyl)-(4-nitro-phenylsulfanyl)-amino]-acetamide
ID: ALA292431
PubChem CID: 10595804
Max Phase: Preclinical
Molecular Formula: C15H14N4O6S
Molecular Weight: 378.37
Molecule Type: Small molecule
This compound is available for customization.
Associated Items:
Names and Identifiers
Canonical SMILES: O=C(CN(Cc1ccc([N+](=O)[O-])cc1)Sc1ccc([N+](=O)[O-])cc1)NO
Standard InChI: InChI=1S/C15H14N4O6S/c20-15(16-21)10-17(9-11-1-3-12(4-2-11)18(22)23)26-14-7-5-13(6-8-14)19(24)25/h1-8,21H,9-10H2,(H,16,20)
Standard InChI Key: DCSHLVVGHNRVCO-UHFFFAOYSA-N
Molfile:
RDKit 2D
26 27 0 0 0 0 0 0 0 0999 V2000
7.2542 -4.3167 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
5.7000 -8.8250 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
5.1792 -6.1250 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
4.1375 -6.1250 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
4.6625 -6.4250 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.7000 -8.2250 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.7375 -4.6250 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
7.7750 -4.6250 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
5.1792 -9.1250 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
5.7000 -6.4250 0.0000 S 0 0 0 0 0 0 0 0 0 0 0 0
7.2542 -3.7250 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
6.2250 -9.1250 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
3.6250 -6.4250 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
4.1375 -5.5250 0.0000 N 0 0 0 0 0 0 0 0 0 0 0 0
5.1792 -5.5250 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.2167 -7.9250 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.2125 -4.3167 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.1750 -7.9250 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.7375 -5.2250 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.7000 -7.0250 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.7000 -5.2250 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.2167 -7.3250 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.1750 -7.3250 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
5.7000 -4.6250 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
6.2167 -5.5250 0.0000 C 0 0 0 0 0 0 0 0 0 0 0 0
3.6250 -5.2250 0.0000 O 0 0 0 0 0 0 0 0 0 0 0 0
2 6 1 0
3 15 1 0
4 5 1 0
5 3 1 0
6 18 2 0
7 1 1 0
8 1 1 0
9 2 1 0
10 3 1 0
11 1 2 0
12 2 2 0
13 4 2 0
14 4 1 0
15 21 1 0
16 22 2 0
17 7 1 0
18 23 1 0
19 7 2 0
20 10 1 0
21 25 2 0
22 20 1 0
23 20 2 0
24 17 2 0
25 19 1 0
26 14 1 0
24 21 1 0
16 6 1 0
M CHG 4 1 1 2 1 8 -1 9 -1
M END
Associated Targets(Human)
Molecule Features
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
Drug Indications
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanisms of Action
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Calculated Properties
Molecular Weight: 378.37 | Molecular Weight (Monoisotopic): 378.0634 | AlogP: 2.52 | #Rotatable Bonds: 8 |
Polar Surface Area: 138.85 | Molecular Species: NEUTRAL | HBA: 8 | HBD: 2 |
#RO5 Violations: ┄ | HBA (Lipinski): 10 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): ┄ |
CX Acidic pKa: 8.75 | CX Basic pKa: ┄ | CX LogP: 2.21 | CX LogD: 2.19 |
Aromatic Rings: 2 | Heavy Atoms: 26 | QED Weighted: 0.31 | Np Likeness Score: -0.83 |
References
1. Scozzafava A, Supuran CT.. (2000) Protease inhibitors: synthesis of potent bacterial collagenase and matrix metalloproteinase inhibitors incorporating N-4-nitrobenzylsulfonylglycine hydroxamate moieties., 43 (9): [PMID:10794702] [10.1021/jm990594k] |